ozanimod MS
Selected indexed studies
- Multiple sclerosis. (Nat Rev Dis Primers, 2018) [PMID:30410033]
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. (Cells, 2022) [PMID:35805142]
- Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. (Mult Scler Relat Disord, 2021) [PMID:33454584]
_Worker-drafted node — pending editorial review._
Connections
ozanimod MS is a side effect of
Sources
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (2023) pubmed
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (2024) pubmed
- Multiple sclerosis. (2018) pubmed
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. (2022) pubmed
- Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. (2021) pubmed
- Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. (2021) pubmed
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases. (2025) pubmed
- Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis. (2024) pubmed
- Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2020) pubmed
- An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. (2021) pubmed